$18.5MSep 25, 2026
SCYNEXIS INC
ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULA
View on USAspending.gov → · Award 75A50126C00007 · Definitive Contract